bluebird bio Inc(NASDAQ:BLUE) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Feb 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $1.552M. Analysts estimated a revenue of $1.760M. The revenues were -11.82% below the estimates. Earnings per share were $-1.88. The reported EPS was below estimates by -1.08%. Analysts had estimated an EPS of $-1.86.
In a different note, On Feb 6, 2017, Roth Capital said it Downgrades its rating on bluebird bio Inc. The shares have been rated ‘Neutral’ by the firm.
bluebird bio Inc (BLUE) shares turned negative on Wednesdays trading session with the shares closing down -2.25 points or -2.95% at a volume of 5,42,863. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $76.85. The peak price level was also seen at $76.85 while the days lowest was $73.95. Finally the shares closed at $74. The 52-week high of the shares is $81.25 while the 52-week low is $35.37. According to the latest information available, the market cap of the company is $2,760 M.
Several Insider Transactions has been reported to the SEC. On Feb 17, 2017, James Mandell (director) sold 1,050 shares at $80.22 per share price.Also, On Feb 17, 2017, Daniel Lynch (director) sold 150 shares at $80.22 per share price.On Feb 17, 2017, Jason Cole (Chief Legal Officer) sold 666 shares at $80.22 per share price, according to the Form-4 filing with the securities and exchange commission.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.